Skip to main content
. Author manuscript; available in PMC: 2019 Oct 2.
Published in final edited form as: Curr Opin Immunol. 2019 Mar 15;59:1–8. doi: 10.1016/j.coi.2019.02.001

Figure 1. The proposed roles of the pre-existing cross-reactive immunity to DENV during subsequent ZIKV infection, and vice versa.

Figure 1.

Cross-reactive Abs mediate neutralizing, enhancing or negligible effects during subsequent infection with heterologous virus. Cross-reactive CD8+ T cells provide protection against subsequent infection with heterologous virus.